NASDAQ:ADMA - ADMA Biologics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.84 +0.03 (+0.62 %)
(As of 07/22/2018 06:48 AM ET)
Previous Close$4.84
Today's Range$4.80 - $4.89
52-Week Range$2.01 - $5.70
Volume97,794 shs
Average Volume273,485 shs
Market Capitalization$219.33 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
ADMA Biologics logoADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Debt-to-Equity Ratio1.76
Current Ratio4.92
Quick Ratio3.60

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.76 million
Price / Sales9.64
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book5.44

Profitability

EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-101.93%
Return on Equity-88.31%
Return on Assets-25.76%

Miscellaneous

Employees295
Outstanding Shares45,320,000
Market Cap$219.33

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) released its earnings results on Monday, May, 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.08. The biotechnology company earned $4.04 million during the quarter, compared to analyst estimates of $7.47 million. ADMA Biologics had a negative return on equity of 88.31% and a negative net margin of 101.93%. View ADMA Biologics' Earnings History.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Friday, August, 10th 2018. View Earnings Estimates for ADMA Biologics.

What price target have analysts set for ADMA?

4 Wall Street analysts have issued 12-month price targets for ADMA Biologics' stock. Their predictions range from $5.00 to $13.00. On average, they expect ADMA Biologics' stock price to reach $8.8750 in the next year. This suggests a possible upside of 83.4% from the stock's current price. View Analyst Ratings for ADMA Biologics.

What is the consensus analysts' recommendation for ADMA Biologics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
  • Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
  • Mr. Brian Lenz, VP & CFO (Age 46)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

Has ADMA Biologics been receiving favorable news coverage?

Press coverage about ADMA stock has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ADMA Biologics earned a news impact score of 0.11 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 43.70 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $4.84.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $219.33 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]


MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.